94 completed, 39 unknown, 30 recruiting, 14 terminated. 202 Phase 3, 35 Phase 2.
Follow Tablets: new trials by email Literature Review of Tablets trials Research Report on Tablets
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| This Randomized, Clinical Trial Evaluates the Efficacy of Oral Versus Sublingual Vitamin B12 Supplementation in Correcting Early-onset Vitamin B12 Deficiency in Adult Patients Using Proton Pump Inhibitors (PPIs). The Primary Outcome is the Change in Serum Vitamin B12 Levels Over a 6-week Cyanocobalamin 1000 Mcg Oral Tablet, Cyanocobalamin 1000 Mcg Sublingual Tablet, Proton Pump Inhibitor therapy only - Hypovitaminosis b 12 | Phase 3 | Not yet recruiting | Tanta University | 23 | 2026-12-30 | 2025-05-13 |
| Efficacy and Safety of Combination Therapy Compared With Monotherapy in Patients With Benign Prostatic Hyperplasia Finasteride 5 mg Tablet, single dose, Tamsulosin 0.4Mg Capsule - Benign Prostatic Hyperplasia | Phase 3 | Not yet recruiting | Il-Yang Pharm. Co., Ltd. | 660 | 2026-11-09 | 2026-10-13 |
| A Study of Avatrombopag in Adults With Aplastic Anemia Who Did Not Respond to, Cannot Receive, or Had Return of Disease After Standard Treatment Avatrombopag 20 mg Oral Tablet - Aplastic Anemia | Phase 2 / Phase 3 | Not yet recruiting | Swedish Orphan Biovitrum | 26 | 2026-07-31 | 2026-08-26 |
| An Evaluation of Treatments for Sustained Clinical Response (18 Months) in Symptomatic Alzheimer's Disease Placebo, Atomoxetine, Metformin 1000 mg Oral Tablet - Alzheimer's Disease (AD), Mild Cognitive Impairment Due to Alzheimer's Disease | Phase 3 | Recruiting | University College, London | 1200 | 2026-07-24 | 2026-07-23 |
| PRE-EMPT: Prospective RandomizEd Evaluation and Management of Premature aTherosclerosis Rosuvastatin 20 Mg Oral Tablet, Colchicine 0.5 MG Oral Tablet Once Daily, Placebo - Coronary Artery Disease Risk Factors Multiple, Coronary Artery Disease Progression | Phase 3 | Recruiting | Duke University | 1500 | 2026-07-21 | 2026-11-10 |
| Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors With Statin for ACS Patients PCSK9 inhibitor plus rosuvastatin 20 mg tab, Rosuvastatin 20 Mg Oral Tablet - Acute Coronary Syndromes | Phase 3 | Not yet recruiting | Assiut University | 120 | 2026-07-01 | 2026-07-30 |
| A Study to Evaluate the Safety, Efficacy, and PK of ONO-2017 in Japanese Patients With POS 2 to 17 Year Olds Cenobamate (tablet) for 12 to < 18 year olds, Cenobamate (syrup) for 2 to < 18 year olds - Partial Epilepsy | Phase 3 | Recruiting | Ono Pharmaceutical Co., Ltd. | 20 | 2026-06-10 | 2026-10-09 |
| Design and Rationale of the COLT Study Colchicine 0.5 MG Oral Tablet, Placebo - Venous Thrombosis Deep (Limbs), Post-thrombotic Syndrome | Phase 3 | Not yet recruiting | Azienda Sanitaria Locale ASL 6, Livorno | 940 | 2026-06-01 | 2026-02-25 |
| Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia LB-102 (50 mg tablet), LB-102 (100 mg tablet), Placebo - Schizophrenia | Phase 3 | Recruiting | LB Pharmaceuticals Inc. | 456 | 2026-03-25 | 2026-07-27 |
| Neuroprotection of Memantine and Rosuvastatin Starch Placebo, Memantine, Rosuvastatin 20 Mg Oral Tablet - Peripheral Nerve Disease | Phase 2 / Phase 3 | Not yet recruiting | Tanta University | 46 | 2026-03-01 | 2026-03-31 |
| A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs TQB2102 Injection, Trifluridine /Tipiracil (TAS-102) tablets / Fruquintinib / Regorafenib tablets - HER2 IHC3+ Advanced Colorectal Cancer | Phase 3 | Not yet recruiting | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | 142 | 2026-03-01 | 2026-03-19 |
| Justification And Evaluation of Baricitinib Plus Corticosteroids Versus corticosteroiDs Alone in pOlymyalgia RhEumatica Baricitinib 4 MG Oral Tablet, Baricitinib 2 MG Oral Tablet, Placebo 4 mg - Polymyalgia Rheumatica (PMR) | Phase 3 | Recruiting | University Hospital, Brest | 140 | 2025-12-18 | 2026-08-26 |
| Effects of Continued Administration of Empagliflozin in Patients With Heart Failure on Active SGLT2 Inhibitor Treatment Admitted for Acute Decompensated Heart Failure Empagliflozin 10 MG Oral Tablet [Jardiance], Placebo - Acute Decompensated Heart Failure (ADHF) | Phase 3 | Recruiting | Christian Schulze | 536 | 2025-12-08 | 2026-11-04 |
| Dapagliflozin for Cardio-renal Protection After ICU Discharge Dapagliflozin 10 MG Oral Tablet [Farxiga], One tablet of placebo of dapagliflozin 10 mg - Heart Failure and Chronic Kidney Disease Post-ICU | Phase 3 | Recruiting | Assistance Publique - Hôpitaux de Paris | 600 | 2025-12-02 | 2026-02-23 |
| Acetyl-leucine in Post-stroke Ataxia Acetyl-Leucine, Placebo, Clopidogrel 75 Mg Oral Tablet - Ischemic Stroke | Phase 3 | Recruiting | Kafrelsheikh University | 200 | 2025-12-01 | 2025-12-10 |
| Bempedoic Acid Versus Statins in Primary-Prevention Patients With Suboptimal Statin Adherence: Effects on LDL-C Reduction and Tolerability Bempedoic Acid 180 MG Oral Tablet, Rosuvastatin 5 mg, Placebo - Cardiovascular | Phase 3 | Not yet recruiting | Sohaib Ashraf | 690 | 2025-11-10 | 2025-11-20 |
| A Study to Assess the Safety of HSK31858 in Participants With Non-Cystic Fibrosis Bronchiectasis HSK31858, tablet - Non-cystic Fibrosis Bronchiectasis | Phase 3 | Recruiting | Haisco Pharmaceutical Group Co., Ltd. | 669 | 2025-09-28 | 2026-06-01 |
| DIrect Oral Anticoagulation and Bioprothesis Aortic Valve Apixaban 5 MG Oral Tablet, Aspirin 75 to 100mg once a day - Aortic Valve Disease | Phase 3 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 1500 | 2025-09-01 | 2025-06-12 |
| Rifaximin for Treatment of Bloating in Children and Adults With Cystic Fibrosis Rifaximin 550 MG Oral Tablet [XIFAXAN], Placebo - Cystic Fibrosis, Abdominal Pain | Phase 2 / Phase 3 | Withdrawn | Wake Forest University Health Sciences | 2025-07-01 | 2025-06-27 | |
| Bioavailability and Bioequivalence Study of ER Torsemide and Spironolactone FDC Tablet in Healthy Subjects 10 mg Torsemide tablet, 25 mg Aldactone (Spironolactone) tablet, FDC (12 mg ER Torsemide + 15mg Spironolactone) tablet - Bioequivalence Study in Healthy Subjects, PK/PD | Phase 3 | Completed | Sarfez Pharmaceuticals, Inc. | 24 | 2025-07-01 | 2026-03-06 |
Showing 20 of 202. Sign in to see all of them.
COVID-19 (6) · Pain (6) · Essential Hypertension (5) · Inflammation (4) · Ischemic Stroke (4) · Migraine Disorders (4) · Pain, Postoperative (4) · Parkinson Disease (4) · Acute Coronary Syndrome (3) · Agnosia (3) · Ancylostomiasis (3) · Ascariasis (3) · Breast Neoplasms (3) · Cardiovascular Diseases (3) · Diabetes Mellitus, Type 2 (3)
Tanta University (11) · GlaxoSmithKline (7) · Ain Shams University (5) · Kafrelsheikh University (5) · Assiut University (4) · Rothman Institute Orthopaedics (4) · AbbVie (prior sponsor, Abbott) (3) · Assistance Publique - Hôpitaux de Paris (3) · Bayer (3) · Daiichi Sankyo (3) · Jennifer Keiser (3) · University of Alabama at Birmingham (3) · ANRS, Emerging Infectious Diseases (2) · Abbott (2) · Boehringer Ingelheim (2)
United States (45) · Egypt (26) · France (20) · Canada (19) · Germany (19) · China (16) · Spain (15) · Italy (14) · United Kingdom (14) · Netherlands (13) · Australia (11) · Denmark (10) · Poland (10) · Russia (10) · Belgium (9)
Janet Benesh (2) · Professor Lars Christian Rump, M.D. (2) · Todd Bertoch, MD (2) · Waldemar A Carlo, MD (2) · Abdulrahman Abdul Hamid Alsaied, Professor (1)
PMID 31867054, PMID 12807523, PMID 16731270, PMID 18190818, PMID 22114906, PMID 24361112, PMID 25962554, PMID 31779508, PMID 33586138, PMID 10190267, PMID 10650325, PMID 10859281, PMID 10919968, PMID 11277825, PMID 11326085, PMID 11529691, PMID 11729302, PMID 11834528, PMID 11895451, PMID 11914403, PMID 11975885, PMID 12213433, PMID 12417828, PMID 12421890, PMID 12430089, PMID 12485966, PMID 12686036, PMID 12730697, PMID 12829554, PMID 12867219, PMID 12908852, PMID 12935835, PMID 12972104, PMID 14607021, PMID 14666956, PMID 15007110, PMID 15331429, PMID 15478042, PMID 15553600, PMID 15591005, PMID 15755765, PMID 15849374, PMID 15855667, PMID 15951714, PMID 16003294, PMID 16034009, PMID 16377285, PMID 16384561, PMID 16461820, PMID 16554528
2009 (2), 2015 (2), 2017 (2), 2023 (2), 2005 (1), 2008 (1), 2016 (1), 2019 (1), R01AG048349 (1), R01AG061091 (1), R01HL160982 (1), R56AG055416 (1), UG3HL181434 (1)